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Abstract 
A selective, specific and stability-indicating gradient reverse phase high-
performance  liquid chromatographic (HPLC) method was developed for the 
determination of Ranitidine in presence of its impurities, forced degradation 
products and placebo substances such as saccharide and parabens. Ultraviolet 
detection was performed at 230 nm. Separate portions of the drug product and 
ingredients were exposed to stress conditions to induce oxidative, acidic, basic, 
hydrolytic, thermal and photolytic degradation. Ranitidine was found to degrade 
significantly at acidic, basic and oxidative stress conditions but was stable at 
heat and humidity. The developed method was validated as per International 
Conference on Harmonization (ICH) guidelines. The method was validated over 
this range for (i) system suitability (ii) specificity, (iii) precision, (iv) limit of 
detection and limit of quantification, (v) linearity, (vi) accuracy, (vii) robustness. 
The method was found to be precise, accurate, linear and robust. The proposed 
method was successfully employed for estimation of Ranitidine impurities in 
pharmaceutical preparations. 
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Introduction 
Ranitidine hydrochloride (HCl), USP, is a histamine H2-receptor antagonist. Chemically it 
is (Z)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitro-
ethene-1,1-diamine hydrochloride (Fig. 1). 
Many analytical approaches are available for the related substances of ranitidine in tablet 
formulations and drug substances [1–3]. A number of assay methods for determination of 
ranitidine in pharmaceutical formulations and human plasma is also available [4–6]. 
However, all the above-mentioned methods are orientated to the determination of the 
active pharmaceutical compound. Now-a-days, pharmaceutical industry is forced to 
assess a strict control of impurities when manufacturing drug substance and drug 
products. Determination of impurities during the development of separation methods is one 
of the main and difficult tasks for pharmaceutical analysts, especially if more and more 
impurities of closely related structure require determination. Methods are available for 
estimation of related substance in ranitidine with capillary electrophoresis [7, 8].  
To the best of our knowledge, none of the currently available analytical methods can 
separate all the known related compounds and degradation impurities of ranitidine 
hydrochloride dosage form. Attempts were made to develop a stability indicating LC 
method for estimation of related substance of ranitidine in liquid orals (syrups). The 
published Ranitidine impurity method demonstrates analysis of estimation of Ranitidine 
impurities in presence of placebo like saccharide and parabens with detection wavelength 
at 230 nm. This paper deals with the forced degradation of ranitidine syrup under stress 
condition like acid hydrolysis, base hydrolysis, oxidation, heat and UV light. This paper 
also deals with the validation of the developed method for the accurate quantification of 
impurities of ranitidine. 
Experimental 
The empirical formula of Ranitidine Hydrochloride is C13H22N4O3S•HCl, representing a 
molecular weight of 350.87. 1 mL of ranitidine Syrup contains 16.8 mg of ranitidine HCl 
equivalent to 15 mg of ranitidine. 
Chemicals and reagents 
Syrup and standards of ranitidine and its seven impurities namely imp-A, imp-B, imp-C, 
imp-D, imp-E, imp-F and imp-G (Fig. 1) were supplied by Dr. Reddy’s laboratories limited, 
Hyderabad, India. The HPLC grade acetonitrile, and analytical grade KH2PO4 and ortho 
phosphoric acid were from Merck, Darmstadt, Germany. Water was purified by a Millipore 
(Bedford, MA, USA) Milli-Q water-purification system and passed through a 0.22  µm 
membrane filter (Durapore; Millipore, Dublin, Ireland) before use.  
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Equipment 
The waters HPLC PDA 2996 system used consists of a Quaternary solvent manager, a 
sample manager and a Photodiode array UV detector. The output signal was monitored 
and processed using empower software. Water baths equipped with MV controller (Julabo, 
Seelbach, Germany) were used for hydrolysis studies. Photo stability studies were 
performed in a photo stability chamber, UV light (200 watt hours / square meter), sun light 
(1.2 Million Lux hours) Calibrated (Sanyo, Leicestershire, UK). Thermal stability studies 
were performed in a dry air oven (MACK Pharmatech, Hyderabad, India). 
Chromatographic Conditions 
The analytes were separated on (100 x 4.6 mm, 3 µm) ACE C18 column with mobile 
phase containing a gradient mixture of solvent A and B at column oven temperature of 
40
oC with a gradient run program at a flow-rate of 1.0 mL  min
−1
.  0.05 M potassium 
dihydrogen orthophosphate buffer, pH adjusted to 6.5 with orthophosphoric acid was used 
as buffer. Buffer and acetonitrile in 98:2 v/v ratios was used as solvent A and MilliQ water 
and acetonitrile in 5:95 v/v ratio was used as solvent B. The separation was achieved by 
gradient elution (T/%B) set as 0/0, 10/5, 25/15, 35/20, 40/55, 55/0 and 60/0. The mobile 
phase was filtered through a nylon membrane (pore size 0.45 µm) and degassed with a 
helium spurge for 10 min, before use. UV detection was performed at 230 nm. The sample 
injection volume was 40 µl.  
Preparation of Stock Solutions 
A standard stock solution (Stock A) of ranitidine (0.65 mg/mL) prepared by dissolving 72 
mg Ranitidine hydrochloride of reference standard in 100 mL solvent-A. Working solutions 
of 32.5 µg/mL (Stock-B) diluting stock-A 5.0 mL to 50 mL with solvent-A and 1.625 µg/mL 
(Stock-C) diluting stock-B 5.0 mL to 100 mL with solvent-A were prepared for the related 
substance determination.  
The impurity stock solution was prepared by dissolving an accurately weighed amount of 
impurity A, imp-B, imp-C, imp-D, imp-E, imp-F and imp-G in Solvent-A, resulting in a 
concentration of 0.088 mg/mL (Stock-D) of (2.2 mg each impurity in 25 mL volumetric 
flask) of each impurity. 
System suitability solution containing (0.33 mg/mL) 30 mg Ranitidine and 1.76 µg/mL 
(2 mL of Stock-D) each impurity was also prepared. 
Preparation of Sample Solution 
2 mL ranitidine syrup (equivalent to 30 mg ranitidine and 33.3mg ranitidine HCl.) was 
transferred to a 100 mL volumetric flask, 50 mL solvent A was added. The mixture was 
then sonicated for 10  minute and diluted to volume to give a solution containing 
300 μg/mL. The above solution was centrifuged at 4000rpm for 10 minutes in order to 
eliminate insoluble excipients. This solution was filtered through a 0.45 μm pore size Nylon 
66 membrane filter and inject in HPLC system as per chromatographic conditions mention 
in section 2.3. 
Method Validation 
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Specificity 
Specificity is the ability of the method to measure the analyte response in the presence of 
its potential impurities. A study was conducted to demonstrate the effective separation of 
Ranitidine Hydrochloride and its impurities. Also study was intended to ensure the effective 
separation of degradation peaks of formulation ingredients at the retention time of 
Ranitidine Hydrochloride and its impurities. Separate portions of drug product and 
ingredients were exposed to following stress conditions to induce degradation. 
The drug product was subjected to base hydrolysis using 0.1 N Sodium hydroxide, acid 
hydrolysis with 0.1N Hydrochloric acid for duration of 30 minute. Oxidation study was 
performed with 0.1 % Hydrogen Peroxide solution at room temperature for 30 minute. On 
photo stability study, drug product was sufficiently spread on Petri plates (1 mm thick 
layer), exposed to sunlight and UV light (200 watt hours / square meter), sun light (1.2 
Million Lux hours) at ambient conditions for 10 days. Humidity study was performed 
separately by exposing the drug product to humidity at 25°C, 90% RH for 7 days. Thermal 
degradation study was performed by heating drug product at 60° C for 10 days. Similarly 
placebo samples were prepared as like as drug product by exposing formulation matrices 
without drug substance. 
Peak purity test was carried out for the ranitidine peak by using PDA detector in stress 
samples.  
Precision 
The precision of the related substance method was checked by injecting six individual 
preparations of ranitidine (0.3 mg/mL) spiked with 0.50% of imp-A, imp-B, imp-C, imp-D, 
imp-E, imp-F and imp-G with respect to ranitidine analyte concentration. % R.S.D. of area 
for each imp-A, imp-B, imp-C, imp-D, imp-E, imp-F and imp-G was calculated.  
The intermediate precision of the method was also evaluated using different analyst and 
different instrument in the same laboratory. 
Limits of Detection (LOD) and Quantification (LOQ) 
The LOD and LOQ for imp-A, imp-B, imp-C, imp-D, imp-E, imp-F and imp-G were 
determined at a signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a series of 
dilute solutions with known concentrations. LOD and LOQ were experimentally verified by 
injecting six replicate injection of each impurity at the concentration obtained from above 
values. 
Linearity 
A series of solutions of Ranitidine impurities in the concentration ranging from limit of 
quantification level to 300% of standard concentration were prepared and injected into the 
HPLC system. Correlation coefficient Value for the slope and Y-intercept of the calibration 
curve was calculated. 
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phase buffer pH 6.8 
 
Column Oven Temperature 50° C 
 
Using XterraRP18 100*4.6 mm, 3µ Column 
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Accuracy 
To confirm the accuracy of the proposed method, recovery studies were carried out by 
standard addition technique. The accuracy study of impurities were carried out in triplicate 
at LOQ, 50%, 100%, 150%, 200% and 300% of the target concentration level 0.5% of 
ranitidine analyte concentration (300 µg/mL). The percentages of recoveries for impurities 
were calculated.  
Robustness 
To determine the robustness of the developed method, experimental conditions were 
deliberately altered and the resolution between ranitidine imp-A, imp-B, imp-C, imp-D, 
imp-E, imp-F and imp-G was recorded. The flow rate of the mobile phase was 1.0 mL/min. 
To study the effect of flow rate on the resolution, flow was changed by 0.2 units from 0.8 to 
1.2 mL/min. The effect of the column temperature on resolution was studied at 35° and 43° 
C instead of 40° C. The effect of the percent organic strength on resolution was studied by 
varying acetonitrile by −10% +10%. While other mobile phase components was held 
constant as stated in Section 2.3. 
Solution Stability and Mobile Phase Stability 
The solution stability of ranitidine and its impurities in the related substance method was 
carried out by leaving spiked sample solutions in tightly capped volumetric flasks at room 
temperature for 48 hours. Content of ranitidine imp-A, imp-B, imp-C, imp-D, imp-E, imp-F 
and imp-G were determined for every 24 hours interval up to the study period. The mobile 
phase stability was also carried out for 48 hours by injecting the freshly prepared sample 
solutions for every 24 hours interval. Content of ranitidine imp-A, imp-B, imp-C, imp-D, 
imp-E, imp-F and imp-G were checked in the test. 
Results and Discussion 
Method Development and Optimization 
The main criteria for development of a successful HPLC method for determination of 
Ranitidine HCl and its related Substances in oral solution were: the method should be able 
to determine all substances in a single run and should be accurate, reproducible, robust, 
stability indicating, free of interference from blank / placebo / impurities / degradation 
products and straightforward enough for routine use in quality control laboratory.  
The main objective of the chromatographic method was to achieve good resolution 
between critical closely eluting pair ranitidine impurity-D and impurity-E, to well resolve 
impurity-C peak from placebo peak, and to find Symmetrical peak shape of Ranitidine 
Hydrochloride and its Impurities. To elute parabens peaks, a gradient elution with 95 % 
acetonitrile in the solvent B has been selected. In order to achieve symmetrical peak of 
Ranitidine Hydrochloride and its Impurity and more resolution between impurity-D and 
impurity-E, stationary phases like C18 (different brand), ACE C18 250 x 4.6, 5µ column, 
Xterra RP 18 100 x 4.6 mm, 5µ, Xterra RP18 100 x 4.6, 3.5µ (Fig. 2) were studied but 
good resolution has achieved with ACE C18 100 x 4.6, 3µ column (Fig. 3). The flow rate of 
1.0 mL/min was selected with regards to the backpressure and analysis time as well. 
Column oven temperature is also studied (50°C and 40°C) and found that 40°C 
temperature is more appropriate with respect to resolution and peak shape (Fig. 2). 316 N.  Sharma  et al.:  
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Attempts were also made with gradient elution with solvents A and B (Section 2.3) using 
pH 6.8 buffer conditions, the resolution between impurity C and placebo peak was 
decreased (Fig. 2).  
It was found that use of buffer prepared by adjusting the pH of 0.05M potassium 
dihydrogen phosphate to 6.5 (PKa of Ranitidine is 8.2) with orthophosphoric acid (solvent 
A: buffer, acetonitrile in the ratio 98:2, v/v and solvent B: Milli Q water, acetonitrile in the 
ratio 5:95, v/v) with column temperature was maintained at 40° C and gradient elution 
(T/%B) was set as 0/0, 10/5, 25/15, 35/20, 40/55, 55/0 and 60/0 gives enabled separation 
for all pair compounds and eluted Ranitidine as a symmetrical peak (Fig. 3 and table 1). 
No interfering peaks were observed in blank & placebo, indicating that signal suppression 
or enhancement by the product matrices was negligible (Fig. 3). 
The empirical formula of Ranitidine Hydrochloride is C13H22N4O3S•HCl, representing a 
molecular weight of 350.87. Each 1 mL of ranitidine Syrup contains 16.8 mg of ranitidine 
HCl equivalent to 15 mg of ranitidine. 
Validation of the Method  
System Suitability  
System suitability parameters were measured so as to verify the system, method and 
column performance. Results of other system suitability parameters such as relative 
retention time of each impurity, resolution between Impurity E and Impurity D, tailing factor 
and similarity factor (between two standard preparations) are presented in table 1. As seen 
from this data, the acceptable system suitability parameters would be: relative retention 
time of each impurity should comparable, resolution between Impurity E and Impurity D is 
not less than 1.5, Tailing factor for Ranitidine peak in standard solution is not more than 
2.0, similarity factor (between two standard preparations) is not less than 0.98 and not 
more than 1.02. Spiked chromatogram of impurity / degradation products with Ranitidine is 
presented in Figure 2. 
Tab. 1.  System Suitability 
Compound name  RT  RRT
a Tailing  factor 
IMP F  1.42  0.10  1.3 
IMP-E 2.42  0.18  1.4 
IMP-D 3.10  0.23  1.4 
IMP-A 4.45  0.32  1.5 
IMP-C 5.78  0.42  1.1 
IMP-G 11.41  0.84  1.1 
Ranitidine 13.75  1.00 1.1 
IMP-B 27.357 1.96  1.4 
Similarity factor for two standard preparations observed 0.99; 
Resolution between Impurity E and Impurity D observed 1.71. 
a Relative retention times (RRT) were calculated against the 
retention time (RT) of Ranitidine. 
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Specificity 
All forced degradation samples were analyzed at an initial concentration of Ranitidine with 
HPLC conditions mentioned in Section 2.3 using PDA detector to ensure the homogeneity 
and purity of Ranitidine peak. Significant degradation of Ranitidine was observed in 
oxidative (1.0% H2O2 at 60 ◦C for 30 minutes), Acid (0.1 N HCl at 60 ◦C for 30 minutes) 
and Base (0.1 N NaOH at 60 ◦C for 30 minutes) conditions leading to the formation of 
impurities. % Degradation has summarized in table 2. 
Tab. 2.  Specificity 
Drug Product  Stress Condition 
%
a  Imp-A Imp-B Imp-C Imp-D Imp-E Imp-F Imp-G
Refluxed with 0.1N HCl 
solution for about 30 min  
at 60°C 
11.3  0.59 0.01 0.14 4.64 4.78 0.11 1.18 
Refluxed with 0.1N NaOH 
solution for about 30 min  
at 60°C 
12.4  1.11 0.02 0.30 0.05 0.09 0.36  10.85 
Refluxed with 0.1% 
Hydrogen peroxide for  
about 30 min at 60°C 
7.9 0.13 0.03 6.65 0.09 0.03 NIL 1.19 
Exposed to Sunlight for 
about 1.2 Million Lux hrs  4.5 0.54 0.03 0.99 0.01 0.03 NIL 0.07 
Exposed to UV light both  
at shorter and longer 
wavelengths for about 
200 watt hrs / m
2 
1.6 0.30 0.04 0.64 0.02 0.02 NIL 0.04 
Dry heating done at  
60°C for about 12 hrs  0.3 0.19 0.04 0.23 NIL 0.03 NIL 0.06 
a % degradation. 
 
Precision  
The % R.S.D. for the area of ranitidine imp-A, imp-B, imp-C, imp-D, imp-E, imp-F and imp-
G in related substance method precision study was within 2%, conforming good precision 
of the method. To check reproducibility of method Intermediate precision study has been 
performed in same laboratory with different day on different HPLC system and column. % 
RSD values presented in table 3. 
Limits of Detection and Quantification  
The determination limit of detection, limit of quantification of all the impurities namely 
ranitidine imp-A, imp-B, imp-C, imp-D, imp-E, imp-F and imp-G are reported in table 3. The 
precision at the LOQ concentrations for ranitidine imp-A, imp-B, imp-C, imp-D, imp-E, imp-
F and imp-G were below 7.5 %. LOD, LOQ values presented in table-3 
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Linearity  
The result shows that an excellent correlation existed between the peak area and 
concentration of the analyte. Linear calibration plot for the related substance method was 
obtained over the calibration ranges tested, i.e. LOQ to 300 % for impurity imp-A, imp-B, 
imp-C, imp-D, imp-E, imp-F and imp-G. The correlation coefficient obtained was greater 
than 0.997 (table 3). The above result show that an excellent correlation existed between 
the peak area and the concentration of imp-A, imp-B, imp-C, imp-D, imp-E, imp-F and 
imp-G. 
Tab. 3.  LOD, LOQ values, Regression and Precision Data. 
Parameter Imp-A  Imp-B  Imp-C  Imp-D 
LOD (μg/ml) 0.02  0.01  0.01  0.01 
LOQ (μg/ml) 0.08  0.05  0.03  0.04 
Regression equation (y)       
Slope (b) 800058.78 110376.41 104469.9  126925.17
Intercept (a)  −5220.21  −5142.23  −761.31  −982.74 
Correlation  coefficient  0.997  0.999 0.999 0.999 
Precision (%RSD)  0.1  0.4 0.4 0.1 
Intermediate precision (%RSD)  0.2  0.4 0.2 0.3 
Parameter Imp-E  Imp-F  Imp-G   
LOD (μg/ml) 0.01  0.01  0.02   
LOQ (μg/ml) 0.04  0.04  0.08   
Regression equation (y)       
Slope (b) 81026.01  55442.92  58284.3   
Intercept (a)  −1541.70  −1746.62  −1206.81  
Correlation coefficient  0.997  0.999  0.999   
Precision (%RSD)  0.1  0.1  0.5   
Intermediate precision (%RSD)  0.2  0.2  0.4   
 
Tab. 4.  Evaluation of Accuracy 
% Accuracy  Amount  
Spiked    Imp-A Imp-B Imp-C Imp-D Imp-E Imp-F Imp-G
% Recovery  92.9  101.1 96.0 96.0 94.4  101.8  100.1  LOQ 
%  RSD  4.2 3.0 6.0 4.0 0.0 3.4 6.3 
% Recovery  95.7  100.9 105.1 101.7 102.0 93.9 101.1  50 % 
%  RSD  0.37 1.27 0.22 0.39 0.39 1.83  1.2 
% Recovery  101.9 102.4 98.5 99.3  101.3  93.2 97.5  100 % 
%  RSD  0.40 0.70 0.30 0.20 0.29 0.12  0.5 
% Recovery  106.0 102.2 98.2  99.6  102.1  94.6  98  150 % 
%  RSD  0.84 0.20 0.20 0.26 0.60 0.31  0.5 
% Recovery  98.7  102.1 99.2 98.8  101.3  98.7 97.1  200 % 
%  RSD  0.54 0.10 0.15 0.23 0.25 0.58  0.2 
% Recovery  98.1  101.0 99.6 99.7  100.5  99.1 98.5  300 % 
%  RSD  0.10 0.10 0.15 0.20 0.16 0.25  0.1 
% RSD values calculated with three sample recovery at each level.   A Validated Stability-Indicating Liquid-Chromatographic Method for Ranitidine Hydrochloride …  321 
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Accuracy  
The percentage recovery of impurities in ranitidine samples varied from 90 to 110 % at 
LOQ, 50%, 100%, 150%, 200% and 300 % levels of target 0.5 % level. The LC 
chromatogram of spiked sample at 0.5% level of all seven impurities in ranitidine oral 
solution is shown in figure 2. % Recovery values for impurities are presented in table 4. 
Robustness  
In all the deliberate varied chromatographic conditions (flow rate, column temperature and 
composition of organic solvent), the resolution between critical pairs, i.e. imp-D and imp-E 
was greater than 1.5, illustrating the robustness of the method. 
Stability in Solution and in the Mobile Phase  
No significant changes were observed in the content of impurities namely imp-A, imp-B, 
imp-C, imp-D, imp-E, imp-F and imp-G during solution stability and mobile phase stability 
experiments when performed using the related substance method. The solution stability 
and mobile phase stability experiment data confirms that the sample solutions and mobile 
phases used during related substance determination were stable for 48 hours. 
Conclusions 
The gradient HPLC method developed for ranitidine and related substances in 
pharmaceutical dosage forms is precise, accurate, linear, robust, rugged and specific. 
Satisfactory results were obtained from validation of the method. The method is stability-
indicating and can be used for routine analysis of production samples and to check the 
stability of samples of ranitidine. 
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